WO2009033818A3 - Use of a peptide as a therapeutic agent - Google Patents

Use of a peptide as a therapeutic agent Download PDF

Info

Publication number
WO2009033818A3
WO2009033818A3 PCT/EP2008/008186 EP2008008186W WO2009033818A3 WO 2009033818 A3 WO2009033818 A3 WO 2009033818A3 EP 2008008186 W EP2008008186 W EP 2008008186W WO 2009033818 A3 WO2009033818 A3 WO 2009033818A3
Authority
WO
WIPO (PCT)
Prior art keywords
leu
glu
gly
lys
arg
Prior art date
Application number
PCT/EP2008/008186
Other languages
French (fr)
Other versions
WO2009033818A2 (en
Inventor
Dorian Bevec
Fabio Cavalli
Vera Cavalli
Gerald Bacher
Original Assignee
Mondobiotech Lab Ag
Dorian Bevec
Fabio Cavalli
Vera Cavalli
Gerald Bacher
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mondobiotech Lab Ag, Dorian Bevec, Fabio Cavalli, Vera Cavalli, Gerald Bacher filed Critical Mondobiotech Lab Ag
Publication of WO2009033818A2 publication Critical patent/WO2009033818A2/en
Publication of WO2009033818A3 publication Critical patent/WO2009033818A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • A61K38/35—Corticotropin [ACTH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention is directed to the use of the combination of the peptide compounds Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-Gly-Lys-Lys-Arg- Arg-Pro-Val-Lys-Val-Tyr-Pro-Asn-Gly-Ala-Glu-Asp-Glu-Ser-Ala-Glu-Ala-Phe-Pro-Leu- Glu-Phe-OH and Leu-Gln-Asn-Arg-Arg-Gly-Leu-Asp-Leu-Leu-Phe-Leu-Lys-Glu-Gly- Gly-Leu-OH as a therapeutic combination for prophylaxis and/or treatment of cancer, a heart and vascular disease, an infectious disease, a fibrotic disease, an inflammatory disease, a neurodegenerative disease, or an autoimmune disease.
PCT/EP2008/008186 2007-09-11 2008-09-09 Use of a peptide as a therapeutic agent WO2009033818A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP07017752.2 2007-09-11
EP07017762 2007-09-11
EP07017762.1 2007-09-11
EP07017752 2007-09-11

Publications (2)

Publication Number Publication Date
WO2009033818A2 WO2009033818A2 (en) 2009-03-19
WO2009033818A3 true WO2009033818A3 (en) 2009-06-11

Family

ID=40427387

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/008186 WO2009033818A2 (en) 2007-09-11 2008-09-09 Use of a peptide as a therapeutic agent

Country Status (1)

Country Link
WO (1) WO2009033818A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010054446A1 (en) * 2008-11-11 2010-05-20 Ademovic Zlatko Combination of two or more peptides in a single stable lyophilized pharmaceutical compound
US20140294923A1 (en) * 2013-02-20 2014-10-02 Questcor Pharmaceuticals, Inc. Acth for treatment of migraine headache
WO2019236938A1 (en) 2018-06-07 2019-12-12 Ovid Therapeutics Inc. Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigabatrin in the treatment of developmental disorders

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995032311A1 (en) * 1994-05-23 1995-11-30 Calypte, Inc. Non-hiv antibodies as disease markers
FR2860004A1 (en) * 2003-09-18 2005-03-25 Roussy Inst Gustave Adenoviral vector encoding modified capsid protein, useful in gene therapy of e.g. cancer and cystic fibrosis, can infect cells deficient in, or lacking, the common receptor for Coxsackie virus B3 and adenovirus
US20070185025A1 (en) * 2005-09-11 2007-08-09 The Trustees Of Columbia University In The City Of New York Filoviral immunosuppressive peptides and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995032311A1 (en) * 1994-05-23 1995-11-30 Calypte, Inc. Non-hiv antibodies as disease markers
FR2860004A1 (en) * 2003-09-18 2005-03-25 Roussy Inst Gustave Adenoviral vector encoding modified capsid protein, useful in gene therapy of e.g. cancer and cystic fibrosis, can infect cells deficient in, or lacking, the common receptor for Coxsackie virus B3 and adenovirus
US20070185025A1 (en) * 2005-09-11 2007-08-09 The Trustees Of Columbia University In The City Of New York Filoviral immunosuppressive peptides and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
MEHROTRA SHIKHAR ET AL: "Immunomodulation by peptide analogs of retroviral envelope protein.", PEPTIDES (NEW YORK), vol. 24, no. 7, July 2003 (2003-07-01), pages 979 - 985, XP002519623, ISSN: 0196-9781 *

Also Published As

Publication number Publication date
WO2009033818A2 (en) 2009-03-19

Similar Documents

Publication Publication Date Title
WO2009033821A3 (en) Use of a peptide as a therapeutic agent
WO2009043522A3 (en) Use of a peptide as a therapeutic agent
WO2009043518A3 (en) Use of a combination of cart peptides as a therapeutic agent
LTC2435432I2 (en) Apoptosis-causing agents for the treatment of cancer and immune and autoimmune diseases
HK1110526A1 (en) Medicaments for the treatment or prevention of fibrotic diseases
WO2009033819A3 (en) Use of glicentin-related polypeptide and apelin- 13 in combination as therapeutic agents, eg for treating aids
WO2006058867A3 (en) Substituted pteridines for the treatment of inflammatory diseases
WO2007135026A3 (en) Substituted pteridines as therapeutic agents
IL184124A0 (en) Medicaments for the treatment or prevention of fibrotic diseases
WO2012061390A3 (en) Therapeutic compositions and methods
WO2009043525A3 (en) Use of the combination of gluten exorphin c and cd36 as a therapeutic agent
WO2010094734A3 (en) Methods for identifying and compounds useful for the diagnosis and treatment of diseases involving inflammation
WO2009033813A3 (en) Use of a peptide as a therapeutic agent
WO2009033818A3 (en) Use of a peptide as a therapeutic agent
WO2009033814A3 (en) Use of the peptide combination thymosin beta 4 and delta sleep inducing peptide as a therapeutic agent
WO2009033820A3 (en) Use of saralasin and carbetocin in combination to treat of eg aids or idiopathic pulmonary fibrosis
WO2009033809A3 (en) Use of a peptide as a therapeutic agent
WO2009033816A3 (en) Use of the combination of thymosin beta 10 and thymosin alpha 1 peptides as a therapeutic agent
WO2009046875A3 (en) Combination of splenopentin and thymopentin and the use thereof in medicine
WO2008009426A9 (en) 5-cyano-prostacyclin derivatives as agents for the treatment of autoimmune diseases
WO2009043523A3 (en) Cortistatin 17 and neuropeptide 1 for use as therapeutic agent
WO2009043519A3 (en) Use of band 3 protein and pacap-27 as a therapeutic agent
WO2009074498A8 (en) Medical use of 3- (2, 2, 2-trimethylhydrazinixm) propionate orotate
WO2009046872A3 (en) Use of a peptide as a therapeutic agent
WO2009033812A3 (en) Use of a combination of neuropeptide-ff and alpha-msh as a therapeutic agent

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08802643

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08802643

Country of ref document: EP

Kind code of ref document: A2